Related Experiment Video
Updated: Jun 8, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
How should we treat vascular and fibrotic lung disease in scleroderma?
Jared N Kravitz1, Charlie Strange
1Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina 96 Jonathan Lucas St, Suite 812 CSB, Charleston, SC 29425 USA.
Abstract:
Recent randomized trials suggest that evidence-based algorithms for systemic sclerosis can be developed to identify patients at risk for lung disease, follow lung disease progression, and modify disease with therapies of proven benefit. Recognition of disease subsets allows physicians to integrate physiology, overlapping disease manifestations, and predictable drug effects into a comprehensive disease management program.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
COPD: Management Using Bronchodilators and Corticosteroids
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment

